{"organizations": [], "uuid": "ba75548f3640e5326c31c27fab3d42f434df8028", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-puma-biotechnology-and-medison-pha/brief-puma-biotechnology-and-medison-pharma-enter-licensing-agreement-to-commercialize-nerlynx-in-israel-idUSFWN1PP0U2", "country": "US", "domain_rank": 408, "title": "BRIEF-Puma Biotechnology And Medison Pharma Enter Licensing Agreement To Commercialize Nerlynx In Israel", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-30T15:29:00.000+02:00", "replies_count": 0, "uuid": "ba75548f3640e5326c31c27fab3d42f434df8028"}, "author": "", "url": "https://www.reuters.com/article/brief-puma-biotechnology-and-medison-pha/brief-puma-biotechnology-and-medison-pharma-enter-licensing-agreement-to-commercialize-nerlynx-in-israel-idUSFWN1PP0U2", "ord_in_thread": 0, "title": "BRIEF-Puma Biotechnology And Medison Pharma Enter Licensing Agreement To Commercialize Nerlynx In Israel", "locations": [], "entities": {"persons": [{"name": "licensi", "sentiment": "negative"}], "locations": [{"name": "israel", "sentiment": "none"}, {"name": "israel", "sentiment": "none"}], "organizations": [{"name": "medison pharma", "sentiment": "negative"}, {"name": "commercialize nerlynx in israel reuters staff", "sentiment": "none"}, {"name": "puma biotechnology inc", "sentiment": "none"}, {"name": "puma biotechnology inc - co", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "medison", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "puma", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 30, 2018 / 1:29 PM / in 13 minutes BRIEF-Puma Biotechnology And Medison Pharma Enter Licensing Agreement To Commercialize Nerlynx In Israel Reuters Staff 1 Min Read \nJan 30 (Reuters) - Puma Biotechnology Inc: \n* PUMA BIOTECHNOLOGY AND MEDISON PHARMA ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE NERLYNXÂ® (NERATINIB) IN ISRAEL \n* PUMA BIOTECHNOLOGY INC - CO, MEDISON PHARMA LTD ENTERED INTO EXCLUSIVE AGREEMENT UNDER WHICH MEDISON WILL COMMERCIALIZE NERLYNX IN ISRAEL \n* PUMA BIOTECHNOLOGY SAYS WILL RECEIVE UPFRONT, MILESTONE PAYMENTS THROUGHOUT AGREEMENT TERM, & DOUBLE DIGIT ROYALTIES ON NERLYNX SALES IN ISRAEL \n* PUMA BIOTECHNOLOGY SAYS EXPECT TO RECEIVE REGULATORY APPROVAL FOR NERLYNX IN ISRAEL DURING H1 2019 Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-30T15:29:00.000+02:00", "crawled": "2018-01-30T15:50:20.002+02:00", "highlightTitle": ""}